Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Cash from Financing Activities (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Cash from Financing Activities for 3 consecutive years, with -$121000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 303.33% to -$121000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9000.0 through Dec 2025, down 100.0% year-over-year, with the annual reading at $9000.0 for FY2025, 99.99% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$121000.0 at Artiva Biotherapeutics, down from -$37000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $163.9 million in Q3 2024, with the low at -$121000.0 in Q4 2025.
  • Average Cash from Financing Activities over 3 years is $23.5 million, with a median of $104500.0 recorded in 2024.
  • The sharpest move saw Cash from Financing Activities surged 599.38% in 2024, then plummeted 303.33% in 2025.
  • Over 3 years, Cash from Financing Activities stood at $962000.0 in 2023, then plummeted by 103.12% to -$30000.0 in 2024, then tumbled by 303.33% to -$121000.0 in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$121000.0, -$37000.0, and -$72000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.